Clinical Observations in Geriatrics
Published: 2019-12-15

Autoimmune necrotizing myopathy in an octogenarian: a case report

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina
Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina
Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina
Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina
Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina
Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina
Autoimmune necrotizing myopathy Statinization Population ageing Geriatric patients Octogenarians

Abstract

Autoimmune necrotizing myopathy (ANM) is a rare form of immune-mediated myopathy, with less than 200
cases reported worldwide. Its mean age of presentation is of 64 years and only 8 cases of octogenarians
have been described so far. We present the case of NAM in an 82 year-old male patient who consulted with a
3-month painless subacute proximal upper and lower limb weakness that led him to prostration. He had been
taking statins for two years as secondary stroke prevention. His work-up showed high CK levels, a pathological
EMG and a muscular biopsy compatible with necrotizing myopathy. ANM is an infrequent pathology that
has statin use as a known risk factor. In turn, statin prescription has been significantly boosted by the 2013
American Heart Association’s cholesterol treatment guidelines. Unlike younger patients, a mild motor morbidity
in older people can significantly worsen their risk of falls, which is consecutively associated with functional decline,
hospitalization and death. We estimate that given the worldwide population ageing and the statinization
process currently ongoing, geriatric cases will increase in frequency and we believe that due to their extreme
frailty statin indication and close follow-up should be mindfully considered in octogenarians.

INTRODUCTION

Autoimmune necrotizing myopathy (ANM) belongs to the infrequent group of immune-mediated myopathies 1, of which it approximately represents a 10% 2. It was first acknowledged as a distinct entity in 2004 3 and 4 series of patients have been since published, with the largest being of 100 cases 4-8. ANM affects men and woman in an equal fashion with a mean age of presentation of 64 years 4 8. Statin use is the main known risk factor for its development, although approximately 33% of the cases occur without a prior exposure to them 9. In that regard, the 2013 ACC/AHA atherosclerotic cardiovascular prevention guidelines 10 introduced both a new classification method and therapeutic algorithm for blood cholesterol treatment which determined that an estimated 1 billion people worldwide have an indication of statin therapy 11. In addition, global population ageing is also an ongoing trend 12 that associated with the massive use of statins (statinization 11) will probably result in older affected patients who not necessarily have the same therapeutic response and resilience of younger ones 13. So far, there are only eight reported cases of ANM in octogenarian patients 4 6 7 9 14-16 and here we present the case of an 82-year-old patient along with a small review of the currently available literature of ANM focusing in the elderly.

CASE REPORT

An 82-year-old patient was evaluated in our hospital due to a painless subacute mobility restriction that had started 3 months prior to the consult and evolved in the following two months to an inability to walk. He had a history of Chagas disease, acute myocardial infarction, hypertension, alcohol and tobacco abuse, mild cognitive impairment and ischemic stroke without clinical sequelae. He had been taking 10 mg of atorvastatin daily for the past two years and was also treated with carvedilol, enalapril and finasteride. On physical examination he had four limb proximal weakness (Medical Research Council Scale -MRCS-: 3) with no strength limitation in distal muscles (MRCS: 5). He had absent deep tendon reflexes and distal hypopalesthesia. His body mass index was 17. Laboratory findings included CK levels of 3996 U/L, aldolase of 40 U/L, LDH of 898 U/L, AST 282 of U/L, negative HIV and VDRL and normal ionogram, calcium and TSH levels. His EMG showed a chronic polyneuropathy as well as myopathic motor unit potentials in proximal upper and lower limb muscles and spontaneous muscular discharges both in proximal and distal muscles (Fig. 1). A deltoid biopsy was performed which revealed necrotic muscle fibers associated to a macophagic infiltrate (CD 68+), without lymphocytes, amyloid deposits, fiber vacuolization or vasculitis; compatible with a necrotizing myositis (Fig. 2). We were only able to perform anti-SRP testing, for which he was negative. He was started on prednisone 1 mg/kg/day and weekly methrotexate 15 mg, with a slow but steady normalization of his CK levels with no clinical amelioration at two months but with mild strength improvement in his upper limbs (MRCS: 4) at the three month follow-up.

DISCUSSION

ANM is a 15-year-old entity characterized by subacute or chronic proximal generalized weakness associated with elevated CK levels 4 7-9 14, frequent myalgia 4 5 9, exceptional diyphagia 1 17 or extra-muscular involvement 2 and a characteristic non inflammatory muscular biopsy with abundant necrosis 4 5 8 14 18. Its physiopathology is unknown 9 18 19 and it has been associated with HIV infection, connective tissue diseases, malignancy and the use of statins regardless of the type or time of exposure 4 5 7 9 14 17. Two antibodies have been described in association with ANM: anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (Anti-HMGCR) and anti-signal recognition particle (Anti-SRP) 20. Anti-HMGR antibodies are usually present in patients with a history of statin use 6 8 21 who have developed ANM or other inflammatory myopathies 22. Anti-SRP antibodies are also not exclusive of ANM but are less frequently linked to statin exposure 7. ANM has a worse prognosis than the other immunomediated myopathies, with frequent relapses 4 and disabling morbidity 2. Initial treatment is with corticosteroids or intravenous gammaglobulin 9, early associated to a steroid sparing agent such as methrotexate, azathioprine, mycophenolate mofetil, tacrolimus or rituximab 2 19.

This patient is one of the few octogenarians so far reported. Only eight others have been described: 4 men 4 14 16, 3 women 6 9 14 and one patient without sex specification 7. Nazir et al. 8 with their systematic review of 100 cases and Kassardjian et al. 7 with 63 ANM patients (not included in Nazir’s review) are the longest series/analysis of patients reported so far, from which is possible to speculate that even at the expense of the very probable underestimation of the total number of cases, nowadays octogenarians only reach a 5% of the ANM cases.

Our patient delayed the initial consultation since it was done when he was already bedridden in spite of having been symptomatic for three months. This might appear counterintuitive but it can be at least partially explained by his mild cognitive impairment in addition to him being an unbefriended older adult, a social situation that is becoming more and more frequent 23.

He had the typical generalized proximal weakness of myopathies but did not have myalgias, which are present in 16 to 75% of the ANMs depending on the series 4 5 9.

Over the past decade, serum antibodies have become key elements for autoimmune myositis diagnosis and have nowadays clinical defined associated syndromes 20 24. Some of them (myositis-specific antibodies or MSA) are specific immune-mediated muscle pathology whereas the rest (myositis-associated antibodies or MAA) can also be found in connective tissue diseases 20 24. Anti-HMGR and Anti-SRP antibodies belong to the first group and are the only antibodies associated with ANM 1. Since testing against HMGCR is not available in our network hospitals, we could only measure anti-SRP titers, which were normal. Due to the fact that seronegative ANMs have a stronger association with malignancy 2, particularly small cell lung carcinoma and colonic carcinoma 17, we assumed the worst-case scenario and performed a whole body CT scan, which showed no present malignancy.

Our patient’s initial CK levels exceeded 3000 U/L and returned to normal after two months of treatment. CK levels and antibody titers have been reported to correlate with disease activity 2 20 and precede clinical recovery in weeks or months 2 17. Regardless, clinical improvement has been reported to be both immediate 9 or delayed 15 and therefore a better treatment response in our patient cannot be excluded. This was also the case of one of the few octogenarians so far reported 14, while the rest’s recovery was total in one case 16, near complete in two 9 15, unknown due to lost of follow-up in one 4 and not specified in the remaining two 6 7. In spite of these evolutions seeming rather benign, it is imperative to consider due to the frailty of geriatric patients even a mild locomotive disability usually has enough impact to determine a restriction in basic and instrumental activities of daily life 23, and that impact in octogenarians is even bigger 13 26.

Population ageing is noticeable through the entire world 12 and unlike younger patients, older people are prompt to metabolize drugs at more variable rates, suffer from syndromes secondary to multiple etiologies (i.e.: geriatric syndromes) 27 28 and have atypical symptoms for common pathologies 29. In particular, upper and lower extremity weakness has been identified as an independent predisposing factor for falls in the elderly 30 31, which in turn are associated with distress, functional decline, hospitalization and death 27 28.

While in general immunomediated diseases in geriatric patients are rare 32, ANM is strongly associated with the use of statin which are being increasingly indicated since the 2013 American Heart Association guidelines of cholesterol management 10. It suggests moderate intensity regimens as secondary prevention for cardiovascular events in individuals older than 75 years 10. Although there is no consensus in the recommendation for primary prevention in that age group, its prescription is of common practice and will probably also multiply 31.

Our patient had a history of an ischemic neurovascular event with transitory symptoms 8-years prior to the consult and had stopped using (or was never given) statins. Nevertheless, they were re-instaurated in the previous two years for reasons that the patient could not refer. In spite of guidelines and recommendations being based on statistically inferred benefits which surpass the risks of adverse events, we believe it needs to be minded that geriatric patients do not necessarily behave like younger adults and to the best of our knowledge there have been no trials addressing statins-treatment risk-benefit among this population 11 23 31.

In conclusion, we would like to stress that although nowadays a rare entity, given the statinization process we are currently under, ANM incidence could largely increase and in the worldwide population ageing-scenario its associated morbidity could have an even bigger impact than the so far reported. Therefore, we believe that general practitioners as well as neurologists should bear in mind this entity to carefully monitor the evolution as well as to perform a thorough and individual assessment of the risk and benefits of statin use in geriatric patients.

Figures and tables

Figure 1.Electromyography of the right biceps (a) and quadriceps (b). (a) myopathic motor unit action potentials (white arrows) with reduced interference pattern at maximal effort. (b) spontaneous muscular activity (arrowheads: positive sharp waves and fibrillations) at rest.

Figure 2.Deltoid muscle biopsy showing a myofiber necrosis (*) with fragmented eosinophilic cytoplasm, surrounded by a macrophage infiltration. A- Hematoxylin-eosin stain X100. B- Hematoxilin-eosin stain X400. C- CD68 peroxidase-immunohistochemistry marking macrophages. X100.

References

  1. Milone M. Diagnosis and management of immune-mediated myopathies. Mayo Clin Proc. 2017; 92:826-37. DOI
  2. Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018; 20:21. DOI
  3. Hoogendijk JE, Amato AA, Lecky BR. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis (10-12 October 2003, Naarden, The Netherlands). Neuromuscul Disord. 2004; 14:337-45. DOI
  4. Grable-Esposito P, Katzberg HD, Greenberg SA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010; 41:185-90. DOI
  5. Christopher-Stine L, Casciola-Rosen LA, Hong G. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010; 62:2757-66. DOI
  6. Mammen AL, Chung T, Christopher-Stine L. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme. A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011; 63:713-21. DOI
  7. Kassardjian CD, Lennon VA, Alfugham NB. Clinical features and treatment outcomes of necrotizing autoimmune Myopathy. JAMA Neurol. 2015; 72:996-1003. DOI
  8. Nazir S, Lohani S, Tachamo N. Statin-associated autoimmune myopathy: a systematic review of 100 cases. J Clin Rheumatol. 2017; 23:149-54. DOI
  9. Nichols L, Pfeifer K, Mammen AL. An unusual case of statin-induced myopathy: anti-HMGCoA necrotizing autoimmune myopathy. J Gen Intern Med. 2015; 30:1879-83. DOI
  10. Stone NJ, Robinson JG, Lichtenstein AH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B):2889-934. DOI
  11. Ioannidis JP. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA. 2014; 311:463-4. DOI
  12. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature. 2008; 451:716-9. DOI
  13. Carlson C, Merel SE, Yukawa M. Geriatric syndromes and geriatric assessment for the generalist. Med Clin North Am. 2015; 99:263-79. DOI
  14. Needham M, Fabian V, Knezevic W. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007; 17:194-200. DOI
  15. Mygland Å, Ljøstad U, Krossnes BK. Persisting weakness after withdrawal of a statin. Case Reports. 2014; 2014:bcr2013203094. DOI
  16. Canzonieri E, De Candia C, Tarascio S. A severe myopathy case in aged patient treated with high statin dosage. Toxicol Rep. 2017; 4:438-40. DOI
  17. Carroll MB, Newkirk MR, Sumner NS. Necrotizing autoimmune myopathy: a unique subset of idiopathic inflammatory myopathy. J Clin Rheumatol. 2016; 22:376-80. DOI
  18. Padala S, Thompson PD. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis. 2012; 222:15-21. DOI
  19. Allenbach Y, Mammen AL, Benveniste O, Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies (Zandvoort, The Netherlands, 14-16 October 2016). Neuromuscul Disord. 2018; 28:87-99. DOI
  20. Palterer B, Vitiello G, Carraresi A. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy. 2018; 16:5. DOI
  21. Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve. 2013; 48:477-83. DOI
  22. Mammen AL. Necrotizing myopathies: beyond statins. Curr Opin Rheumatol. 2014; 26:679-83. DOI
  23. Chamberlain S, Baik S, Estabrooks C. Going it alone: a scoping review of unbefriended older adults. Can J Aging. 2018; 37:1-11. DOI
  24. Ghirardello A, Borella E, Beggio M. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights. 2014; 5:69-75. DOI
  25. Iwaya T, Doi T, Seichi A. Characteristics of disability in activity of daily living in elderly people associated with locomotive disorders. BMC Geriatr. 2017; 17:165. DOI
  26. Reuben DB. Medical care for the final years of live: “When you’re 83, it’s not going to be 20 years”. JAMA. 2009; 302:2686-94. DOI
  27. Cesari M, Marzetti E, Canevelli M. Geriatric syndromes: how to treat. Virulence. 2017; 8:577-85. DOI
  28. Inouye SK, Studenski S, Tinetti ME. Geriatric syndromes: clinical, research and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007; 55:780-91. DOI
  29. Arai H, Ouchi Y, Yokode M. Toward the realization of a better aged society: messages from gerontology and geriatrics. Geriatr Gerontol Int. 2012; 12:16-22. DOI
  30. Tinetti ME, Inouye SK, Gill TM. Shared risk factors for falls, incontinence, and functional dependence. Unifying the approach to geriatric syndromes. JAMA. 1995; 273:1348-53. DOI
  31. Curfman G. Risk of statin therapy in older adults. JAMA Intern Med. 2017; 177:966. DOI
  32. Vadasz Z, Haj T, Kessel A. Age-related autoimmunity. BMC Medicine. 2013; 11:94. DOI

Affiliations

C. Quarracino

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina

N. Pérez

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina

P.J. Landi

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina

L. Paz

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina

G. Gómez

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina

P. Santoro

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina

Copyright

© Società Italiana di Gerontologia e Geriatria (SIGG) , 2019

How to Cite

[1]
Quarracino, C., Pérez, N., Landi, P., Paz, L., Gómez, G. and Santoro, P. 2019. Autoimmune necrotizing myopathy in an octogenarian: a case report. JOURNAL OF GERONTOLOGY AND GERIATRICS. 67, 4 (Dec. 2019), 249-253.
  • Abstract viewed - 3 times
  • PDF downloaded - 0 times